A coordinated stroke treatment program to prevent recurrent thromboembolic events

被引:74
作者
Ovbiagele, B
Saver, JL
Fredieu, A
Suzuki, S
McNair, N
Dandekar, A
Razinia, T
Kidwell, CS
机构
[1] Univ Calif Los Angeles, Med Ctr, Stroke Ctr, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Med Ctr, Dept Neurol, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Med Ctr, Dept Nursing, Los Angeles, CA 90095 USA
关键词
D O I
10.1212/01.WNL.0000140493.83607.F1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To assess the impact of the Preventing Recurrence of Thromboembolic Events through Coordinated Treatment ( PROTECT) Program on achievement of its eight secondary prevention goals at the time of discharge. Methods: Achievement rates for the eight program goals at time of discharge were compared in all patients discharged from a university hospital-based stroke service with a diagnosis of ischemic stroke or TIA during a 1-year period after implementation of the PROTECT Program vs rates obtained from a comparable group of patients admitted to the same service during the preceding year. Results: Demographic and medical features were comparable in the baseline and intervention cohorts for all patients with cerebral ischemia presumed due to large-vessel atherosclerosis or small-vessel disease ( baseline year n = 117, intervention n = 130). Implementation rates in patients without specific contraindications increased for all four medication goals: 97 to 100% for antithrombotic agents, 68 to 97% for statins, 42 to 90% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 14 to 70% for diuretics. Although data were not collected on baseline lifestyle instruction rates, instruction in the program's four lifestyle interventions was achieved by discharge in 100% of the intervention cohort. Conclusion: Implementation of this single-center, systems-based, inhospital program to initiate secondary stroke prevention therapies was associated with a substantial increase in treatment utilization at the time of hospital discharge.
引用
收藏
页码:1217 / 1222
页数:6
相关论文
共 44 条
[1]   New strategies for prevention of ischemic stroke: The LIFE study [J].
Harold P. Adams .
Current Neurology and Neuroscience Reports, 2003, 3 (1) :46-51
[2]   Antithrombotic and thrombolytic therapy for ischemic stroke [J].
Albers, CW ;
Amarenco, P ;
Easton, JD ;
Sacco, RL ;
Teal, P .
CHEST, 2001, 119 (01) :300S-320S
[3]  
*AM HEART ASS GET, COR ART DIS PIL TEST
[4]  
[Anonymous], 1995, Am J Public Health, V85, P183
[5]   The verdict from ALLHAT - Thiazide diuretics are the preferred initial therapy for hypertension [J].
Appel, LJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (23) :3039-3042
[6]   Stroke, statins, and cholesterol - A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors [J].
Blauw, GJ ;
Lagaay, AM ;
Smelt, AHM ;
Westendorp, RGJ .
STROKE, 1997, 28 (05) :946-950
[7]   Why do patients with atrial fibrillation not receive warfarin? [J].
Bungard, TJ ;
Ghali, WA ;
Teo, KK ;
McAlister, FA ;
Tsuyuki, RT .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (01) :41-46
[8]   INTRACRANIAL BRANCH ATHEROMATOUS DISEASE - A NEGLECTED, UNDERSTUDIED, AND UNDERUSED CONCEPT [J].
CAPLAN, LR .
NEUROLOGY, 1989, 39 (09) :1246-1250
[9]  
*CDC P COV PIL REG, 2003, STROKE, V34, P288
[10]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252